Image Source: WOWNEWS24X7
Aurobindo Pharma’s subsidiary Eugia Pharma Specialities announced the launch of Pomalidomide Capsules in the U.S. after receiving FDA approval. Available in 1 mg, 2 mg, 3 mg, and 4 mg strengths, the drug is used in treating multiple myeloma, strengthening Aurobindo’s oncology portfolio in America.
Show more
Key Highlights
-
Product launch: Eugia Pharma Specialities, a wholly owned arm of Aurobindo Pharma, has introduced Pomalidomide Capsules in the U.S. market.
-
FDA approval: The U.S. FDA approved the capsules in multiple strengths (1 mg, 2 mg, 3 mg, 4 mg), confirming bioequivalence and therapeutic efficacy.
-
Therapeutic use: Pomalidomide is prescribed for patients with multiple myeloma, particularly those who have received prior treatments.
-
Strategic significance: This launch enhances Aurobindo’s oncology portfolio and strengthens its presence in the U.S. generics market, a key growth driver for the company.
-
Market outlook: Analysts view this as a positive step in diversifying Aurobindo’s product pipeline, especially in high-value therapeutic areas like oncology.
-
Regulatory context: The launch follows recent FDA inspections of Eugia’s facilities, underscoring the company’s compliance and readiness for global expansion.
This milestone positions Aurobindo Pharma as a stronger player in the U.S. oncology generics space, reflecting its strategy to expand into complex, high-demand therapies.
Sources: FDA Database, CNBC TV18, FDA Approval Letter
Stay Ahead – Explore Now!
Avio Smart Market Stack Seals Strategic Pact with Huwel to Revolutionize TB Diagnostics in India
Advertisement
STORIES YOU MAY LIKE
Image Source: Instagram
Updated: March 03, 2026 19:07
Image Source: Instagram
Updated: March 02, 2026 20:39
Image Source: SharkTank India
Updated: March 01, 2026 20:47
Advertisement